Trial Profile

A Phase Ib Study of Safety and Efficacy of APG-1252 in Combination With Osimertinib (AZD9291) in EGFR TKI Resistant NSCLC Patients

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osimertinib (Primary) ; Palcitoclax (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Sponsors Ascentage Pharma

Most Recent Events

24 Oct 2023 Updated (As of Feb16,2023, n=64) safety and efficacy results of this combination therapy presented at the 48th European Society for Medical Oncology Congress
23 Oct 2023 According to Ascentage Pharma media release, the results from this trial were presented at the 2023 ESMO Congress.
23 Oct 2023 Results published in the Ascentage Pharma Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com